Digest Network How does it work
Network
/
Society
Or
Not verified

Organon & Co.

What we write about

BiotechnologyHealthMedicine - variousPharmaceuticalsWindows / Shopping

36 Press releases

View all press releases
25/11/2025
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
WEB AND SOCIAL NETWORK
Eventi
Finance
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Source
Organon & Co.
Issuer
Business Wire
1.00
0
17/11/2025
Oncology
Health
Food hygiene
Windows / Shopping
Pharmaceuticals
Biotechnology
Industria
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Source
Organon & Co.
Issuer
Business Wire
1.00
0
10/11/2025
Health
Medical and health
Windows / Shopping
Pharmaceuticals
Cardiology
Biotechnology
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Organon Reports Results for the Third Quarter Ended September 30, 2025
Source
Organon & Co.
Issuer
Business Wire
1.00
0
08/11/2025
Eventi
Industria
Scienza
Pharmaceuticals
Health
Children
Windows / Shopping
Medicine - various
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
Source
Organon & Co.
Issuer
Business Wire
1.00
0
07/11/2025
Health
Medical and health
Windows / Shopping
Medicine - various
Pharmaceuticals
Biotechnology
Organizzazione Aziendale
Labour market
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
Source
Organon & Co.
Issuer
Business Wire
1.00
0
06/11/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
Finance
stock market
Biotechnology
Windows / Shopping
Health
Pharmaceuticals
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
Source
Organon & Co.
Issuer
Business Wire
1.00
0
19/09/2025
Multimedia
Oncology
Health
Medicine - various
Pharmaceuticals
Biotechnology
Industria
La Commissione europea (CE) approva BILDYOS® (denosumab) e BILPREVDA® (denosumab) di Henlius e Organon, biosimilari rispettivamente di PROLIA (denosumab) e XGEVA (denosumab)
Source
Organon & Co.
Issuer
Business Wire
1.00
0
19/09/2025
Multimedia
Oncology
Health
Medicine - various
Pharmaceuticals
Biotechnology
Industria
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Source
Organon & Co.
Issuer
Business Wire
1.00
0
02/09/2025
Multimedia
Food hygiene
Medicine - various
Sanità
Biotechnology
Pharmaceuticals
Windows / Shopping
Health
Oncology
Industria
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Source
Organon & Co.
Issuer
Business Wire
1.00
0
05/08/2025
Health
Medical and health
Windows / Shopping
Pharmaceuticals
Cardiology
Biotechnology
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Stocks and shares
Organon Reports Results for the Second Quarter Ended June 30, 2025
Source
Organon & Co.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0